Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Novel coronavirus and culture method thereof as well as novel coronavirus inactivated vaccine

A technology of coronavirus and culture method, applied in the field of vaccines, to achieve the effect of fast value-added, good passage stability, and high culture titer

Active Publication Date: 2020-10-13
广东省疾病预防控制中心 +2
View PDF4 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

As a new infectious disease, the new coronavirus has not yet produced a new coronavirus inactivated vaccine for human use

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Novel coronavirus and culture method thereof as well as novel coronavirus inactivated vaccine
  • Novel coronavirus and culture method thereof as well as novel coronavirus inactivated vaccine
  • Novel coronavirus and culture method thereof as well as novel coronavirus inactivated vaccine

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0069] Isolation, cultivation and identification of embodiment 1 K-T13 strain

[0070] 1. Sample processing

[0071] The K-T13 strain claimed in the present invention is isolated from samples of patients infected with the new coronavirus.

[0072] In a biosafety level 3 laboratory, the specimens are handled accordingly:

[0073] Add appropriate amount of MEM to the sputum bottle of the sputum sample submitted for inspection by a patient infected with the new coronavirus, vortex for 2 to 3 minutes to fully homogenize the sputum, and place it at room temperature. If no antibiotics were added, directly add double antibodies to a final concentration of 1000U / mL, and transfer to cryopreservation tubes.

[0074] Second, the configuration of the experimental solution

[0075]

[0076] Remarks: If the MEM medium contains glutamine, it can no longer be added; if the MEM medium does not contain glutamine, it is necessary to add a 1% (V / V) concentration of 200mM glutamine solution....

Embodiment 2

[0103] Embodiment 2 Inactivation of new coronavirus

[0104] (1) Virus harvest solution (37°C when harvested), equilibrate to 2-8°C before adding inactivator;

[0105] (2) β-propiolactone (stored at -20°C), put it on ice during use to ensure the temperature is below 2-8°C, and quickly return it to -20°C after use;

[0106] (3) Add the inactivator β-propiolactone into the virus harvesting solution (2-8°C) in different proportions, shake it evenly, and transfer it to a new storage bottle with a sterile pipette;

[0107] (4) Set up a negative control, add the inactivator (β-propiolactone) into the cell maintenance solution according to different proportions, shake it evenly, and transfer it to a new storage tube with a sterile pipette;

[0108] (5) Place the sample after adding the inactivator at 2-8°C for inactivation, and shake it once at a certain interval, and the frequency is higher at the beginning;

[0109] (6) After an appropriate time of inactivation, perform a 37°C wa...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to the field of vaccines, in particular to a novel coronavirus and a culture method thereof as well as a novel coronavirus inactivated vaccine. The novel coronavirus was preserved in China Center for Type Culture Collection on July 28th, 2020, with the preservation number of CCTCC NO: V202039 and the strain name of 2019-nCoV / K-T13. The invention provides a strain of the novelcoronavirus, the strain has high culture titer, fast proliferation and good passage stability, and the antigenic determinant (RBD) regional sequence of the strain is still not changed obviously evenif the strain is passed for more than 18 generations, so that the strain is suitable for large-scale culture of viruses and is suitable for being used as a vaccine strain. The optimal inactivation condition of the strain is further determined, and the novel coronavirus inactivated vaccine is obtained for the first time.

Description

technical field [0001] The present invention relates to the field of vaccines, in particular, to a novel coronavirus, a cultivation method thereof, and an inactivated vaccine of the novel coronavirus. Background technique [0002] Severe acute respiratory syndrome coronavirus 2, or translated as severe acute respiratory syndrome coronavirus 2, severe acute respiratory syndrome coronavirus 2 (Severe acute respiratory syndrome coronavirus 2, SARS-CoV-2) is a A positive-sense, single-stranded RNA virus of the membrane, belonging to the Coronaviridae Betacoronavirus genus severe acute respiratory syndrome-associated coronavirus species. Its gene sequence and SARS virus and MERS virus belong to the same lineage but different clades. It is the seventh known coronavirus that can infect humans. The hosts of the virus include mammals and birds, which caused the outbreak of coronavirus disease 2019 (COVID-19) in late 2019. The SARS-CoV-2 virus can invade the human body through the h...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): C12N7/00C12N7/06A61K39/215A61P31/14C12R1/93
CPCC12N7/00A61K39/12A61P31/14C12N2770/20021C12N2770/20051C12N2770/20063C12N2770/20034A61K2039/5252
Inventor 袁润余柯昌文周平平柯碧霞安文琪马小伟张海燕黎薇武婕
Owner 广东省疾病预防控制中心
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com